REGULATORY

Takeda Takes Over Development of Glatiramer Acetate from Teva: Official

October 21, 2014

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Takeda Pharmaceutical took over the development of glatiramer acetate in Japan from Teva Pharmaceutical K.K., a health ministry official has told Jiho. The Ministry of Health, Labor and Welfare issued a notification on October 16, revoking orphan drug designation granted…

To read the full story

Takeda to Market Teva’s Multiple Sclerosis Treatment in Japan
December 5, 2013

REGULATORY

Japan Drug Prices to Fall 4% in FY2026 Revision: Official Gazette
March 5, 2026
Romiplate to See Steepest Cut in April Market Expansion Re-Pricing
March 5, 2026
MHLW Clarifies Use of Real-World Data in Drug Applications
March 5, 2026
MHLW Expands Eligibility for “Specific-Use Drug” Designation
March 5, 2026
MHLW to Launch Priority Review Pathway for Overseas Alternatives amid Drug Shortages
March 5, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…